X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
CUBICIN is a lipopeptide antibacterial indicated for the treatment of complicated skin and skin structure infections in adult and pediatric patients, and Staphylococcus aureus bloodstream infections in adult patients including those with right-sided infective endocarditis.
Lead Product(s): Daptomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Cubicin
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
Sandoz acquires the distribution rights in the United States for daptomycin 500mg injection and fosaprepitant 150mg for injection from BE Pharmaceuticals AG.
Lead Product(s): Daptomycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Daptomycin-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
